Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL9051874 | 0.94 | CHRM1 (0.41) | CHRM2CHRM4CHRM1CHRM3NPSR1 | |
| SCHEMBL9050441 | 0.92 | CHRM2 (0.50) | CHRM2CHRM4CHRM1CHRM3NPSR1 | |
| SCHEMBL9052128 | 0.88 | CHRM2 (0.45) | CHRM2CHRM4CHRM1CHRM3NPSR1 | |
| Oxalic Acid SCHEMBL9049463 | 0.88 | CHRM2 (0.47) | CHRM2CHRM4CHRM1CHRM3NPSR1 | |
| SCHEMBL28436716 | 0.86 | HSD11B1 (0.40) | CHRM2CHRM4CHRM1CHRM3NPSR1 | |
| Oxalic Acid SCHEMBL9048446 | 0.83 | CHRM2 (0.42) | CHRM2CHRM4CHRM1CHRM3NPSR1 | |
| SCHEMBL8790010 | 0.79 | CHRM2 (0.41) | CHRM2CHRM4CHRM1CHRM3NPSR1 | |
| SCHEMBL592258 | 0.78 | OPRM1 (0.40) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL7985447 | 0.76 | CHRM2 (0.40) | CHRM2CHRM4CHRM1CHRM3 | |
| Bromide SCHEMBL6628170 | 0.76 | OPRM1 (0.39) | CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | claimed |
| EP-0287356-B1 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1996-01-24 | — | — | EP | claimed |
| EP-0287356-A2 | Bridgehead substituted azabicyclic derivatives | BEECHAM GROUP PLC (GB) | 1988-10-19 | — | — | EP | claimed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| EP-2119716-A1 | AZA-BRIDGED-RING COMPOUND | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-0625981-A1 | AZABICYCLO COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-30 | — | — | EP | disclosed |
| WO-1993015080-A1 | AZABICYCLO COMPOUNDS AS CALCIUM CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | CHRM2 3/4885CHRM4 5/4885CHRM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.